Actinium-225 is a radioisotope used for treatment in targeted alpha therapy. It has a half-life of 10 days. Clinical trials have demonstrated the applicability of radiopharmaceuticals containing 225Ac to treat various types of cancer including leukaemia, prostate cancer and primary tumours.
Rhodotron® TT300 HE
The electrons are accelerated to generate an electron beam at 40 MeV to reach the target
Custom target
226Ra in the target is irradiated creating the 226Ra(g,n)225Ra by photoreaction. The 225Ra will then naturally decay in 225Ac. The Radium target could be solid or liquid target.
After irradiation, the radium could be recycled and reconditioned.
Not provided by IBA
Hardware ready
Process under development
Cyclone® KIUBE
225Ac can also be produced on the Cyclone® KIUBE using a proton beam of 18 MeV
Nirta® solid targets
226Ra in the target is irradiated creating the 226Ra(p,2n)225Ac reaction. The Radium target could be solid or liquid target. After irradiation, the radium could be recycled and reconditioned.
IBA provides only the irradiation station equipment.
Hardware ready
Process under development
Cyclone® IKON
225Ac can also be produced on the Cyclone® IKON using a proton beam of 15-30 MeV
Nirta® Solid target 30 MeV
226Ra in the target is irradiated creating the 226Ra(p,2n)225Ac reaction. The Radium target could be solid or liquid target. After irradiation, the radium could be recycled and reconditioned.
IBA provides only the irradiation station equipment.
Hardware ready
Process under development
Samy Bertrand, Jean-Michel Geets, Cristiana Gameiro, Benoit Nactergal, Jeremy Brison
Willem Leysen, Jakub Damian, Lucia-Ana Popescu, Jasper Mermans, Hanna Skliarova, Dominic Maertens, Stephan Heinitz, Guy Scheveneels, Koen Hasaers, Dennis Elema, Sven Van Den Berghe, Cristiana Gameiro Jean-Michel Geets Samy Bertrand